Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities

Nagihan Tarikci, Emek Kocatürk, Şule Güngör, Ilteriş Oğuz Topal, Pelin Ülkümen Can, Ralfi Singer, Nagihan Tarikci, Emek Kocatürk, Şule Güngör, Ilteriş Oğuz Topal, Pelin Ülkümen Can, Ralfi Singer

Abstract

Pruritus is the most frequently described symptom in dermatology and can significantly impair the patient's quality of life. In 10-50% of adults with persistent pruritus, it can be an important dermatologic clue for the presence of a significant underlying systemic disease such as renal insufficiency, cholestasis, hematologic disorder, or malignancy (Etter and Myers, 2002; Zirwas and Seraly, 2001). This review describes the presence of pruritus in different systemic diseases. It is quite important to discover the cause of pruritus for providing relief for the patients experiencing substantial morbidity caused by this condition.

Figures

Figure 1
Figure 1
Neurological pathways of pruritus.

References

    1. Shanley K. J. Pathophysiology of pruritus. Veterinary Clinics of North America. Small Animal Practice. 1988;18(5):971–981. doi: 10.1016/s0195-5616(88)50101-8.
    1. Yonova D. Pruritus in certain internal diseases. Hippokratia. 2007;11(2):67–71.
    1. Navaz H. Itch: a symptom of occult disease. Australian Family Physician. 2004;33(7):495–499.
    1. Patel T. S., Freedman B. I., Yosipovitch G. An update on pruritus associated with CKD. The American Journal of Kidney Diseases. 2007;50(1):11–20. doi: 10.1053/j.ajkd.2007.03.010.
    1. Narita I., Iguchi S., Omori K., Gejyo F. Uremic pruritus in chronic hemodialysis patients. Journal of Nephrology. 2008;21(2):161–165.
    1. Szepietowski J. C., Salomon J. Uremic pruritus: still an important clinical problem. Journal of the American Academy of Dermatology. 2004;51(5):842–843. doi: 10.1016/j.jaad.2004.04.003.
    1. Attia E. A. S., Hassan A. A. Uremic pruritus pathogenesis, revisited. Arab Journal of Nephrology and Transplantation. 2014;7(2):91–99.
    1. Aucella F., Vigilante M., Gesuete A. Review: the effect of polymethylmethacrylate dialysis membranes on uraemic pruritus. NDT Plus. 2010;3(supplement 1):i8–i11. doi: 10.1093/ndtplus/sfq031.
    1. Morton C. A., Lafferty M., Hau C., Henderson I., Jones M., Lowe J. G. Pruritus and skin hydration during dialysis. Nephrology Dialysis Transplantation. 1996;11(10):2031–2036. doi: 10.1093/oxfordjournals.ndt.a027092.
    1. Yosipovitch G., Reis J., Tur E., Sprecher E., Yarnitsky D., Boner G. Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure. British Journal of Dermatology. 1995;133(4):561–564. doi: 10.1111/j.1365-2133.1995.tb02705.x.
    1. Ståhle-Bäckdahl M. Uremic pruritus. Clinical and experimental studies. Acta Dermato-Venereologica, Supplement. 1989;145:1–38.
    1. Zucker I., Yosipovitch G., David M., Gafter U., Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. Journal of the American Academy of Dermatology. 2003;49(5):842–846. doi: 10.1016/s0190-9622(03)02478-2.
    1. Pisoni R. L., Wikström B., Elder S. J., et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Nephrology Dialysis Transplantation. 2006;21(12):3495–3505. doi: 10.1093/ndt/gfl461.
    1. De Filippi C., Regazzini R., Piazza V., et al. Uraemic pruritus is not related to plasma histamine concentrations. Clinical and Experimental Dermatology. 1995;20(4):294–296. doi: 10.1111/j.1365-2230.1995.tb01328.x.
    1. De Marchi S., Cecchin E., Villalta D., Sepiacci G., Santini G., Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. The New England Journal of Medicine. 1992;326(15):969–974. doi: 10.1056/nejm199204093261501.
    1. Massry S. G., Popovtzer M. M., Coburn J. W., Makoff D. L., Maxwell M. H., Kleeman C. R. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. The New England Journal of Medicine. 1968;279(13):697–700. doi: 10.1056/nejm196809262791308.
    1. Hampers C. L., Katz A. I., Wilson R. E., Merrill J. P. Disappearance of ‘uremic’ itching after subtotal parathyroidectomy. The New England Journal of Medicine. 1968;279(13):695–697. doi: 10.1056/nejm196809262791307.
    1. Jedras M., Zakrzewska-Pniewska B., Wardyn K., Świtalski M. Uremic neuropathy—part II. Is pruritus in dialyzed patients related to neuropathy? Polskie Archiwum Medycyny Wewnetrznej. 1998;99(6):462–469.
    1. Tarng D.-C., Cho Y.-L., Liu H.-N., Huang T.-P. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron. 1996;72(4):617–622. doi: 10.1159/000188949.
    1. Ständer S., Moormann C., Schumacher M., et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Experimental Dermatology. 2004;13(3):129–139. doi: 10.1111/j.0906-6705.2004.0178.x.
    1. Greaves M. W. Itch in systemic disease: therapeutic options. Dermatologic Therapy. 2005;18(4):323–327. doi: 10.1111/j.1529-8019.2005.00036.x.
    1. Kuypers D. R., Claes K., Evenepoel P., Maes B., Vanrenterghem Y. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrology Dialysis Transplantation. 2004;19(7):1895–1901. doi: 10.1093/ndt/gfh202.
    1. Chen Y.-C., Chiu W.-T., Wu M.-S. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. The American Journal of Kidney Diseases. 2006;48(1):69–76. doi: 10.1053/j.ajkd.2006.03.082.
    1. Berger T. G., Steinhoff M. Pruritus and renal failure. Seminars in Cutaneous Medicine and Surgery. 2011;30(2):99–100. doi: 10.1016/j.sder.2011.04.005.
    1. Wang H., Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. International Journal of Dermatology. 2010;49(1):1–11. doi: 10.1111/j.1365-4632.2009.04249.x.
    1. Mettang M., Weisshaar E. Pruritus: control of itch in patients undergoing dialysis. Skin Therapy Letter. 2010;15(2):1–5.
    1. Umeuchi H., Togashi Y., Honda T., et al. Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system. European Journal of Pharmacology. 2003;477(1):29–35. doi: 10.1016/j.ejphar.2003.08.007.
    1. Phan N. Q., Bernhard J. D., Luger T. A., Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. Journal of the American Academy of Dermatology. 2010;63(4):680–688. doi: 10.1016/j.jaad.2009.08.052.
    1. Davis M. P., Frandsen J. L., Walsh D., Andresen S., Taylor S. Mirtazapine for pruritus. Journal of Pain and Symptom Management. 2003;25(3):288–291. doi: 10.1016/S0885-3924(02)00645-0.
    1. Hundley J. L., Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. Journal of the American Academy of Dermatology. 2004;50(6):889–891. doi: 10.1016/j.jaad.2004.01.045.
    1. Gunal A. I., Ozalp G., Yoldas T. K., Gunal S. Y., Kirciman E., Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation. 2004;19(12):3137–3139. doi: 10.1093/ndt/gfh496.
    1. Silva S. R. B., Viana P. C. F., Lugon N. V., Hoette M., Ruzany F., Lugon J. R. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron. 1994;67(3):270–273. doi: 10.1159/000187978.
    1. Murphy M., Carmichael A. J. Renal itch. Clinical and Experimental Dermatology. 2000;25(2):103–106. doi: 10.1046/j.1365-2230.2000.00587.x.
    1. Bunchorntavakul C., Reddy K. R. Pruritus in chronic cholestatic liver disease. Clinics in Liver Disease. 2012;16(2):331–346. doi: 10.1016/j.cld.2012.03.010.
    1. Rishe E., Azarm A., Bergasa N. V. Itch in primary biliary cirrhosis: a patients' perspective. Acta Dermato-Venereologica. 2008;88(1):34–37. doi: 10.2340/00015555-0350.
    1. Bergasa N. V. Pruritus in chronic liver disease: Mechanisms and treatment. Current Gastroenterology Reports. 2004;6(1):10–16. doi: 10.1007/s11894-004-0020-7.
    1. Bergasa N. V. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clinics in Liver Disease. 2008;12(2):385–406. doi: 10.1016/j.cld.2008.02.013.
    1. Bergasa N. V. Pruritus and fatigue in primary biliary cirrhosis. Clinics in Liver Disease. 2003;7(4):879–900. doi: 10.1016/S1089-3261(03)00105-3.
    1. Imam M. H., Gossard A. A., Sinakos E., Lindor K. D. Pathogenesis and management of pruritus in cholestatic liver disease. Journal of Gastroenterology and Hepatology. 2012;27(7):1150–1158. doi: 10.1111/j.1440-1746.2012.07109.x.
    1. Bergasa N. V. The itch of liver disease. Seminars in Cutaneous Medicine and Surgery. 2011;30(2):93–98. doi: 10.1016/j.sder.2011.04.009.
    1. Bolier R., Oude Elferink R. P. J., Beuers U. Advances in pathogenesis and treatment of pruritus. Clinics in Liver Disease. 2013;17(2):319–329. doi: 10.1016/j.cld.2012.11.006.
    1. Murphy G. M., Ross A., Billing B. H. Serum bile acids in primary biliary cirrhosis. Gut. 1972;13(3):201–206. doi: 10.1136/gut.13.3.201.
    1. Greaves M. W. Pathogenesis and treatment of pruritus. Current Allergy and Asthma Reports. 2010;10(4):236–242. doi: 10.1007/s11882-010-0117-z.
    1. Kremer A. E., Bolier R., Van Dijk R., Oude Elferink R. P. J., Beuers U. Advances in pathogenesis and management of pruritus in cholestasis. Digestive Diseases. 2014;32(5):637–645. doi: 10.1159/000360518.
    1. Tandon P., Rowe B. H., Vandermeer B., Bain V. G. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. American Journal of Gastroenterology. 2007;102(7):1528–1536. doi: 10.1111/j.1572-0241.2007.01200.x.
    1. Summey B. T., Jr., Yosipovitch G. Pharmacologic advances in the systemic treatment of itch. Dermatologic Therapy. 2005;18(4):328–332. doi: 10.1111/j.1529-8019.2005.00035.x.
    1. Kremer A. E., Martens J. J. W. W., Kulik W., et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139(3):1008.e1–1018.e1. doi: 10.1053/j.gastro.2010.05.009.
    1. Elferink R. P. J. O., Kremer A. E., Martens J. J. W. W., Beuers U. H. The molecular mechanism of cholestatic pruritus. Digestive Diseases. 2011;29(1):66–71. doi: 10.1159/000324131.
    1. Kremer A. E., van Dijk R., Leckie P., et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56(4):1391–1400. doi: 10.1002/hep.25748.
    1. Sherard G. B., III, Atkinson S. M., Jr. Focus on primary care: pruritic dermatological conditions in pregnancy. Obstetrical and Gynecological Survey. 2001;56(7):427–432. doi: 10.1097/00006254-200107000-00022.
    1. Twycross R., Greaves M. W., Handwerker H., et al. Itch: scratching more than the surface. QJM. 2003;96(1):7–26. doi: 10.1093/qjmed/hcg002.
    1. Gittlen S. D., Schulman E. S., Maddrey W. C. Raised histamine concentrations in chronic cholestatic liver disease. Gut. 1990;31(1):96–99.
    1. Lonsdale-Eccles A., Carmichael A. J. Treatment of pruritus associated with systemic disorders in the elderly: a review of the role of new therapies. Drugs and Aging. 2003;20(3):197–208. doi: 10.2165/00002512-200320030-00004.
    1. Datta D. V., Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50(3):323–332.
    1. Podesta A., Lopez P., Terg R., et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Digestive Diseases and Sciences. 1991;36(2):216–220. doi: 10.1007/BF01300759.
    1. Bloomer J. R., Boyer J. L. Phenobarbital effects in cholestatic liver disease. Annals of Internal Medicine. 1975;82(3):310–317. doi: 10.7326/0003-4819-82-3-310.
    1. Dillon S., Tobias J. D. Ondansetron to treat pruritus due to cholestatic jaundice. The Journal of Pediatric Pharmacology and Therapeutics. 2013;18(3):241–346. doi: 10.5863/1551-6776-18.3.241.
    1. Mayo M. J., Handem I., Saldana S., Jacobe H., Getachew Y., Rush A. J. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45(3):666–674. doi: 10.1002/hep.21553.
    1. Villamil A. G., Bandi J. C., Galdame O. A., Gerona S., Gadano A. C. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. American Journal of Medicine. 2005;118(10):1160–1163. doi: 10.1016/j.amjmed.2005.05.031.
    1. Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatologic Therapy. 2010;23(6):590–596. doi: 10.1111/j.1529-8019.2010.01366.x.
    1. Alpsoy E. Paraneoplastic pruritus and paraneoplastic erythroderma. Turkdem-Archives of the Turkish Dermatology and Venerology. 2013;47:65–68.
    1. Rubenstein M., Duvic M. Cutaneous manifestations of Hodgkin's disease. International Journal of Dermatology. 2006;45(3):251–256. doi: 10.1111/j.1365-4632.2006.02675.x.
    1. Omidvari S. H., Khojasteh H. N., Mohammadianpanah M., Monabati A., Mosalaei A., Ahmadloo N. Long-term pruritus as the initial and sole clinical manifestation of occult Hodgkin's disease. Indian Journal of Medical Sciences. 2004;58(6):250–252.
    1. Lober C. W. Pruritus and malignancy. Clinics in Dermatology. 1993;11(1):125–128. doi: 10.1016/0738-081x(93)90108-o.
    1. Gobbi P. G., Attardo-Parrinello G., Lattanzio G., Rizzo S. C., Ascari E. Severe pruritus should be a B-symptom in Hodgkin's disease. Cancer. 1983;51(10):1934–1936. doi: 10.1002/1097-0142(19830515)51:10<1934::AID-CNCR2820511030>;2-R.
    1. Bartus C. L., Parker S. R. S. Hodgkin lymphoma presenting as generalized pruritus in an adolescent. Cutis. 2011;87(4):169–172.
    1. King N. K. K., Siriwardana H. P. P., Coyne J. D., Siriwardena A. K. Intractable pruritus associated with insulinoma in the absence of multiple endocrine neoplasia: a novel paraneoplastic phenomenon. Scandinavian Journal of Gastroenterology. 2003;38(6):678–680. doi: 10.1080/00365520310001950.
    1. Valsecchi R., Cainelli T. Generalized pruritus: a manifestation of iron deficiency. Archives of Dermatology. 1983;119(8, article 630) doi: 10.1001/archderm.119.8.630.
    1. Karnath B. M. Pruritus: a sign of underlying disease. Hospital Physician. 2005;41:p. 25.
    1. Siegel F. P., Tauscher J., Petrides P. E. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. American Journal of Hematology. 2013;88(8):665–669. doi: 10.1002/ajh.23474.
    1. Heitkemper T., Hofmann T., Phan N. Q., Ständer S. Aquagenic pruritus: associated diseases and clinical pruritus characteristics. Journal der Deutschen Dermatologischen Gesellschaft. 2010;8(10):797–805. doi: 10.1111/j.1610-0387.2010.07463.x.
    1. Diehn F., Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. British Journal of Haematology. 2001;115(3):619–621. doi: 10.1046/j.1365-2141.2001.03161.x.
    1. Saini K. S., Patnaik M. M., Tefferi A. Polycythemia vera-associated pruritus and its management. European Journal of Clinical Investigation. 2010;40(9):828–834. doi: 10.1111/j.1365-2362.2010.02334.x.
    1. Jackson N., Burt D., Crocker J., Boughton B. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. British Journal of Dermatology. 1987;116(1):21–29. doi: 10.1111/j.1365-2133.1987.tb05787.x.
    1. Pieri L., Bogani C., Guglielmelli P., et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica. 2009;94(11):1537–1545. doi: 10.3324/haematol.2009.007047.
    1. Lin O. A., Karim Z. A., Vemana H. P., Espinosa E. V. P., Khasawneh F. T. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS ONE. 2014;9(1) doi: 10.1371/journal.pone.0087026.e87026
    1. Silver R. T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α . Cancer. 2006;107(3):451–458. doi: 10.1002/cncr.22026.
    1. Hasan M. K., Tierney W. M., Baker M. Z. Severe cholestatic jaundice in hyperthyroidism after treatment with 131-iodine. American Journal of the Medical Sciences. 2004;328(6):348–350.
    1. Mullin G. E., Eastern J. S. Cutaneous signs of thyroid disease. American Family Physician. 1986;34(4):93–98.
    1. Ståhle-Bäckdahl M., Hagermark O., Lins L.-E., Torring O., Hilliges M., Johansson O. Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus. Journal of Internal Medicine. 1989;225(6):411–415. doi: 10.1111/j.1365-2796.1989.tb00104.x.
    1. Krajnik M., Zylicz Z. Understanding pruritus in systemic disease. Journal of Pain and Symptom Management. 2001;21(2):151–168. doi: 10.1016/s0885-3924(00)00256-6.
    1. Sener A. B., Kuscu E., Seckin N. C., et al. Postmenopausal vulvar pruritus—colposcopic diagnosis and treatment. Journal of the Pakistan Medical Association. 1995;45(12):315–317.
    1. Serling S. L. C., Leslie K., Maurer T. Approach to pruritus in the adult HIV-positive patient. Seminars in Cutaneous Medicine and Surgery. 2011;30(2):101–106. doi: 10.1016/j.sder.2011.04.004.
    1. Milazzo F., Piconi S., Magni C., et al. Intractable pruritus in HIV infection: immunologic characterization. Allergy. 1999;54(3):266–272. doi: 10.1034/j.1398-9995.1999.00885.x.
    1. Maticic M., Poljak M., Lunder T., Rener-sitar K., Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. Journal of the European Academy of Dermatology and Venereology. 2008;22(7):779–788. doi: 10.1111/j.1468-3083.2008.02676.x.
    1. Moses S. Pruritus. The American Family Physician. 2003;68(6):1135–1145.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅